McMurray JJV, Solomon SD, Lock JP, Massaro JM, Zhu F, Zhou W, Skali H, Lewis EF, Freeman MW, Halvorsen YC Meta-analysis of risk of major adverse cardiovascular events in adults with type 2 diabetes treated with bexagliflozin. Diabetes Obes Metab. 2023;26(3):971-979 - PMID: 38151752 - DOI: 10.1111/dom.15394

Halvorsen YD, Conery AL, Lock JP, Zhou W, Freeman MW Bexagliflozin as an adjunct to metformin for the treatment of type 2 diabetes in adults: A 24-week, randomized, double-blind, placebo-controlled trial. Diabetes Obes Metab. 2023;25(10):2954-2962 - PMID: 37409573 - DOI: 10.1111/dom.15192

Freeman MW, Bond M, Murphy B, Hui J, Isaacsohn J Results From a Randomized, Open-Label, Crossover Study Evaluating the Effect of the Aldosterone Synthase Inhibitor Baxdrostat on the Pharmacokinetics of Metformin in Healthy Human Subjects. Am J Cardiovasc Drugs. 2023;23(3):277-286 - PMID: 36790596 - PMCID: PMC9930700 - DOI: 10.1007/s40256-023-00572-x